Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report
Cancer Reports · 2025
DOI: 10.1002/cnr2.70238 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Maud B A van der Kleij und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlan…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Desensitization, Immunologic, Drug Hypersensitivity, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re‐introduction of imatinib after a hypersensitivity reaction should be considered. Case Here we present a case report of a 68‐year‐old patient with a GIST diagnosis who was re‐introduced to imatinib after a type IV hypersensitivity reaction via desensitization. A desensitization plan, a plan for formulation of low‐dose imatinib capsules, and the essential steps when considering desensitization are discussed.
Conclusion
Our case of a patient with a type IV hypersensitivity reaction after starting imatinib treatment demonstrates that desensitization is a feasible option after serious cutaneous adverse events in specific cases, when done with good interdisciplinary collaboration and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Dermatology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
- Department of Dermatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
ORCID-Profile: Maud B A van der Kleij, Raween W Kalicharan, Yannick S Elshot, Alwin D R Huitema, Thomas Rustemeyer, Neeltje Steeghs
Zitieren
APA
van der Kleij, M. B. A., Bruijn, T. V. M., Kalicharan, R. W., Elshot, Y. S., Pilon, M. C. F., Oostdijk, M., Tibben, M. M., Nuijen, B., Huitema, A. D. R., Rustemeyer, T., & Steeghs, N. (2025). Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70238
Vancouver
van der Kleij MBA, Bruijn TVM, Kalicharan RW, Elshot YS, Pilon MCF, Oostdijk M, et al. Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report. Cancer Reports. 2025. doi:10.1002/cnr2.70238
BibTeX
@article{vanderKleij2025,
author = {van der Kleij, Maud B A and Bruijn, Tristan V M and Kalicharan, Raween W and Elshot, Yannick S and Pilon, Maxime C F and Oostdijk, Mark and Tibben, Matthijs M and Nuijen, Bastiaan and Huitema, Alwin D R and Rustemeyer, Thomas and Steeghs, Neeltje},
title = {Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70238}
}
EUVIMED